ful tasks. It is also a sensitive structure, signalling with efficiency any abnormalities of structure or function. When as simple an apparatus as that for dorsiflexion of the wrist is subject to protracted disorganization after a minor injury in 'tennis elbow' it is not surprising that the complicated mechanism of the back is also often deranged. But there are other factors too. In the common view, the spine is a vital organ, and injuries to this region (as to the head) are especially feared. The widespread concept of the disc as an unstable structure which, with little provocation, 'slips' out of position, and which, once it has done this, is liable at any time to repeat the process, has done nothing to lessen the fear of back injury. Nor, we must admit, has the inability of the medical profession to give confident reassurance to its patients. Surely, apprehension of acute recurrence of pain, and fear of chronic invalidism and, perhaps, financial disaster, are a sufficient reason for the development of neurotic symptoms in such cases. These factors must operate in greater or lesser degree in a high proportion of our patients. Where compensation is also an issue, anxiety over a possible appearance in court, and uncertainty over the outcome are added.
Doubtless all these factors contribute to the severity and duration of disability. It is not necessary to assume that, when a patient makes a claim for compensation, he immediately undergoes a change of character. Some of the statistics which, at first sight, appear to support such a conclusion are based on highly selected material from which most or all patients in whom recovery has been satisfactory have been excluded. Even if a patient is a 'compensation case', justice demands that we assume that his disabilities, physical and psychological, are those of ordinary people, calling for study and, where possible, relief, until or unless we can prove to the contrary. His obituary ends, 'others doubtless will build on the foundations he has laid'. He was the founder of the British Balneological and Climatological Society in 1896 and one of the last actions of that-society before its amalgamation with the Royal Society of Medicine was the foundation of this lecture to perpetuate Hyde's memory.
Ethics ofthe Experimental Trial Anyone who has spent any time in clinical trials will appreciate the formidable problems they present -ethical, administrative, organizational, financial, statistical and practical. I have tried to limit my scope by ignoring the advice of Bismarck (Reid 1954) that, 'only a fool learns from his own experience', by drawing largely on my own experience and the lessons I have learnt from it.
First, let us make no mistake about the fundamental point, that physical medicine is concerned, just as much as any other specialty, with treatment. Not, as some would have it, with treatment isolated from other aspects of medicine diagnosis, pathology, natural history of disease, and so ona view which we all agree is absurd, unsound and totally unscientific; nor is it concerned, as some used to claim, with physical therapy or physiotherapy in similar isolation, an equally absurd view. I make no excuse for quoting, as Bradford Hill did, when writing of the clinical trial (Hill 1951) , the words of Pickering in his Presidential Address to the Section of Experimental Medicine and Therapeutics of this Society (Pickering 1949) : '. . . therapeutics is the branch of medicine that, by its very nature, should be experimental'. 'For if we take a patient afflicted with a malady, and we alter his conditions of life, either by dieting him, or putting him to bed, or by administering to him a drug, or by performing on him an operation', and I might add, by giving him physical treatment, 'we are performing an experiment. And if we are scientifically minded we should record the results. Before concluding that the change for better or for worse in the patient is due to the specific treatment employed, we must ascertain whether the result can be repeated a significant number of times in similar patients, whether the result was merely due to the natural history of the disease or in other words to the lapse of time, or whether it was due to some other factor which was necessarily associated with the therapeutic measure in question. And if, as a result of these procedures, we learn that the therapeutic measure employed produces a significant, though not very pronounced, improvement, we would experiment with the method, altering dosage or other detail to see if it can be improved. This would seem to be the procedure to be expected of men with six years of scientific training behind them. But it has not been followed. ;Had it been done we should have gained a fairly precise knowledge of the place of individual methods of therapy in disease, and our efficiency as doctors would have been enormously enhanced.' Every treatment is, to some extent, an experiment, and we should bear this in mind when considering the ethics of the clinical trial. For which is the least ethical, to submit every patient to an uncontrolled experiment in which we do not know the effects, perhaps long-term effects quite apart from the immediate relief of symptoms, or to submit a group of patients (volunteers of course) to the risk of non-treatment versus treatment? And who is to know which group is submitting itself to greater risk, the group having some 'new' treatment or the group having no treatmentthe control group? Zoxazolamine, a uricosuric agent of great potency, was recently abruptly withdrawn by the manufacturers because of the suggestion that it caused hepatitis. Nor need the treatment be particularly 'new'. For example, radiotherapy is widely accepted as being effective in ankylosing spondylitis and yet the evidence for this appears to be based more on opinion than on data. One of the few controlled studies is that of Desmarais (1953) , but he limited his follow-up to three months and no treatment group exceeded 20 cases. Hart (1958) , whilst accepting that radiotherapy commonly produces symptomatic improvement, wondered whether it altered the natural history: 'our own feeling is', he writes, 'that it does not'. Wilkinson & Bywaters (1958) , in their large series with an adequate follow up, found a high relapse rate. And yet here is a form of treatment whose risks are recognized (Court Brown & Abbott 1955 , Abbott & Lea 1956 , and whose effect on the bone marrow is impressively shown by biopsy before and after irradiation (Stewart 1961) for which no definitive therapeutic trial has been published.
It is remarkable indeed how few experimental trials there are in the literature and, as I have suggested, our specialty is by no means alone in this. On the contrary I believe a careful analysis would show that our contributions would bear investigation in this regard. Proper clinical trials are almost limited to the era following the Second World War. The first proper clinical trial with adequate controls was that into the value of oranges and lemons in the prevention of scurvy in seamen. This is said (Stewart & Guthrie 1953) to be the very first therapeutic trial with matched controls and was carried out by James Lind on sailors aboard H.M.S. Salisbury in 1747 and published in 1753 (Lind 1753 ). It was not, however, until 1795, forty-two years later and after Lind's death, that the Admiralty made a regular issue of lemon juice (Green 1954 ). There are several lessons to be learnt from this trial, the first being that no matter how good a trial is, it does not follow that anyone will believe it. In this particular case there is a second lesson, and I am grateful to Professor A E Ritchie for drawing my attention to it, that not all the deductions made from a trial are necessarily valid, but even if they prove wrong they do not necessarily invalidate the trial. The Admiralty thought simply in terms of 'fruit juice' and issued lime juice to the sailors because this was cheaper. By chance lime contains practically no vitamin C and it therefore failed to prevent, or cure, the scurvy and wrongly suggested that the original experiment was faultyanother simple trap for the unwary.
Controls
The basic problem in the planning of any therapeutic trial centres around the selection of controls. It can be very difficult, but that it is essential to solve it, is, I think, generally agreed, and I suggest that one should actively avoid reading the report of any published therapeutic trial in which there are no controls of any kind. This will inevitably introduce some degree of observer bias, one way or the other. For this reason too, one should usually avoid 'pilot studies' and 'preliminary reports'. Since only 42 % of a recent series of 100 consecutive therapeutic trials in the British Medical Journal and Lancet were ctnsidered to have acceptable controls (Patterson 1962) , this policy will significantly increase the efficient use of reading time.
My first introduction to the need for controls arose from such a preliminary report by Lewin & Wassen (1949) suggesting that the injection of deoxycortone intramuscularly and ascorbic acid intravenously, at the same time, produced a dramatic improvement in patients with rheumatoid arthritis. A blindfold experiment was set up (Quin et al. 1950 ) in which patients acted as their own controls in that they received one test injection and one blank injection, in a balanced random order. Assessed at one hour after the .513 23 514 Proceedings ofthe Royal Society ofMedicine injection of the test substance the results are quite impressive in that over 50 % of the patients were 'better'. But comparing the results of the control injection we found that the 'improvement' was identical. However assessed, the results were identical in this trial and merely illustrate the point that a favourable placebo response can be anticipated in some 30-40% of any group of patients. Morison et al. (1961) , for example, found that 34 % were regular placebo-responders, 37 % occasional responders and 290% nonresponders in a group of arthritic patients subjected to clinical trial. That the placebo response is by no means a simple one has, however, been emphasized by Joyce (1959 Joyce ( , 1961 . In particular he points out that many drugs such as ipecacuanha or atropine, phenobarbitone or dexamphetamine only produce their characteristic effect if, as he puts it, 'the manner of their presentation allows them to do so'. And he also refers to the very interesting work of Uhlenhuth et al. (1959) wherein a statistically significant difference between meprobamate and phenobarbitone on the one hand, and a placebo on the other, only emerged if the physician deliberately adopted an optimistic attitude. If he did not, no difference could be detected. Let no one say therefore, that the placebo response is necessarily bad. It may be essential, and it could be argued that the difference between the good doctor and the bad is related to his ability to elicit such a response in his patients. But we must pay very careful regard to it in planning any trial and, if we consider the physiotherapist with her tremendous opportunities for producing the placebo response, we must recognize that any clinical trial of her work must be designed to use it. Indeed, the placebo component of the physiotherapist's activities might itself be an interesting subject for study. It is not enough merely to have controls, they must be shown to be balanced controls. That is to say, the control group must match the treated group in suitable, preselected criteria. Consider for example, an analysis of the control and treated groups in a recent trial into the value of gold therapy in rheumatoid arthritis (Empire Rheumatism Council 1960) . This trial illustrates the care that must be exercised in establishing the similarity between the control and treated groups so that no unfair bias exists in favour of either group. Such a complex and stratified balance cannot be achieved by simple good fortune and some very nice planning must be done to produce such a result. This involves some central allocation of patients to treatment and control groups. An example of reliance on chance to produce a balanced group of patients was a trial into the value of various treatments in cervical spondylosis carried out at the London Hospital (Steinberg & Mason 1959) . We wanted to be sure that the groups allocated to the various treatments did in fact have about a similar degree of severity of cervical spondylosis. An analysis of the X-rays of the cervical spines categorizing them as slight, moderate or severe spondylosis showed that in fact we were not treating equivalent degrees of severity based on the radiological assessment in the three groups. This was a trial involving 163 patients and clearly simple reliance on numbers and good fortune was insufficient. Stratification of this complexity, however, cannot be done immediately and must be done by a central office; this has the disadvantage of imposing delay since the patient cannot be allocated to a treatment or control group, or the experiment started, on the first occasion the patient is seen. This is an example of some of the administrative and organizational difficulties met in planning an adequate trial. It is of course possible to overcome this difficulty to a large extent by using the patient as his own control, that is to say each patient has a period of treatment and a period as a control. Whilst there are conveniences in this method there are also pitfalls. The order in which the test substance and the control material are administered must be balanced. In a recent trial at the London Hospital (Joyce & Mason 1961) a test substance, a placebo and phenylbutazone were compared in a group of rheumatoid arthritics, being given in random order under double blindfold conditions. One method of assessment was a simple preference question, 'Did you prefer X, Y or Z?' It was clear that the third course of treatment had an advantage over the second, and the second over the first. The design of the experiment, however, was such that no individual substance was able to 'benefit' from this because the 48 patients formed a Latin square design:
Each block was replicated 8 times
This technique may work well enough for drug trials. We may run into difficulties if we try to use the patient as his own control in any trial involving physiotherapy. Consider, for example, the problems of using the patient as his own control in a course of treatment in which any form of exercise or muscle re-education plays a part.
Could we use the contralateral side as a control? Improvement in the un-exercised side has been reported by several workers, for example, Darcus & Salter (1955) . On the other hand, Liberson & Asa (1959) deny that it occurs at all. So not only have we a problem of experimental design here but we lack accepted physiological data. Indeed, this is not all we lackwe lack agreed methods of measurement of power and endurance and even knowledge of their interrelationships. In fact we have probably not reached the point where any reasonable experimental design is possible. We must know much more about so-called 'crosseducation' and as Ritchie (1961, personal communication) puts it, 'The results ofpublished work are so confused in respect of hypertrophy, adaptation, skill and motivation that they are all somewhat suspect'. The work of Benson & Dearnaley (1959) on 'irrelevant muscle activity', and their technique of electromyographic study, seems to be one way around the weakness in experimental trials of the type I have been discussing.
Patient Co-operation Whatever the difficulties of a clinical trial into physical methods of treatment at least we shall be sure of one thing, that the patient is having the treatment. This applies also to any treatment requiring injections such as the gold therapy trial carried out by the Empire Rheumatism Council (1960) . But when tablets have to be taken we cannot be sure what proportion of patients are in fact co-operating. Such evidence as there is, suggests that a significant proportion of patients do not co-operate (Fox 1958) . Clearly this may well produce, by dilution, an insignificant difference between an active drug and a placebo or between one drug and another which could be seriously misleading. In the trial by Joyce & Mason (1961) , in which a test substance was compared with phenylbutazone and a placebo, we endeavoured to assess the degree of patient cooperation by two methods: (a) The insertion of a 'marker' identifiable in the urine, and (b) a count of all returned pills. (a) Marker: 10 mg phenol red was inserted into the tablets of 1 in 2 patients and all urines were tested for this substance at each attendance. It was necessary to give the marker to only half the patients lest any symptoms produced during the period of placebo administration should be attributed to the marker on the supposition that this was behaving as an active drug. In the event the 50 % who had the marker behaved no differently from those who did not, and it was possible therefore to use all the patients in the final analysis. The results of analysing the urines for marker were, however, equivocal, because of an unexpected diminished likelihood of it appearing in the urines of the patients when they were taking either active substance, probably due to an interaction between drug and marker. But it did provide internal evidence confirmatory of the second method of assessing patient co-operation. This evidence is to be reported in detail by Joyce (1962, J. chron. Dis., in press ). (b) Returned pill count: All patients were issued with a known number of pills and instructed to return the unused portion on their next attendance. The number of unused pills was counted and the returned pill count provided some evidence of the degree of co-operation. From a careful analysis of these results it seems as if this method is reasonably reliable.
It was clear that of the total of 80 patients in this trial, 4 had not complied with the instructions in any one month and 27 could not have done so on at least one of the three treatment periods.
Overall it was concluded that at least 47, over 50 %, out of the 80 patients either failed to understand, or to obey, the instructions fully and there is of course only a presumption that the remaining patients were complying. These, however, were classified as 'fully co-operative'.
If we accept this interpretation we could observe differences in the analysis of the results as between the 'co-operators' and the 'non-cooperators'. Certain differences in the attributes of the two groups became apparent. The more cooperative patients showed significantly fewer placebo symptoms and more 'enthusiasm', as measured by the frequency with which they preferred this treatment to that. There were no significant differences in their ages, or in disease duration, but a significant difference in the incidence of marriage appeared, the less cooperative being significantly less often married. The less co-operative patients showed a higher incidence of 'toxicity' to the placebo. Indeed 'toxicity' only showed a meaningful difference if the co-operative group alone are considered. It seems clear, therefore, that the sensitivity of a clinical trial of drug effects is determined to an important extent by the proportion of co-operative patients included, and I suggest that every trial in which it is possible for the patient not to co-operate, must have some inbuilt method of identifying co-operators and non-co-operators.
Differences Between Participating Physicians
It is well recognized that the problem of bias either in favour of or to the disadvantage of any one form of treatment is very important indeed and the experiment must be designed to abolish it altogether. Bias can be avoided by making all the observations under such conditions that the observer can only record what he sees and finds, without any possibility of him knowing whether he is assessing the treatment or the control. This avoids the difficulty of the observer wondering whether he is being prejudiced in recording minor improvement or minor toxic effects. Not only is it important to make it impossible for the observer to guess whether he is assessing a treatment or a control, but this must apply particularly at the point at which a decision is being made as to whether the patient is to be taken into a trial or not. Clearly if the allocation is alternate the physician may have been able to 'guess' that the previous patient was in the treatment group and he is then faced with a patient who, he may think, is likely to go into the control group. He may as a result withhold that patient from the trial because he might feel that it was unfair to put this particular patient into a control group. A bias will then be introduced and the two groups will not be comparable. This incidentally, is one of the arguments against the pilot trial and against publishing preliminary reports suggesting that a certain treatment is effective, or even of carrying out an intermediate analysis the results of which are available to the participating physicians.
The interpretation of X-rays lends itself to useful studies of observer differences since they form a permanent record available for re-study at a later date if necessary. It has been my experience that fatigue is an important factor here and there is a limit to the number of films which can be read at any one sitting. Such fatigue is much reduced by the collaboration of two or three colleagues as a group, although this immediately introduces 'group pressure' and 'conformity' with the group as a factor. In the experiments into the effect of these pressures described by Milgram (1961) , observers had to decide which of two signals received through earphones lasted longer. At the same time, by the use of various tricks including the feeding of false 'taped' information to the observer, pressure was brought to bear on him designed to influence him towards the wrong decision. A measure of his 'conformist trends' could thus be obtained. Norwegians, for example, were found to be very conformist, whilst the French were more independent. The Norwegians, however, accepted criticism stoically whilst 'the French were often enraged'. Clearly there are many factors determining differences between individual observers.
In our recent trial at the London Hospital between 'X', 'Y' and 'Z', discussed above, we made no attempt to balance the allocation of patients to different physicians. It was plain that the overwhelming preference of patients for treatment X was mainly due to the opinions elicited, under completely double-blind conditions of course, by physician B. Had he been excluded from the trial the results would have been far less spectacular. Had he been the only observer the results would have been more spectacular. Physician B seemed to differ from the other physicians in other respects. He also produced fewer reports of toxicity and fewer reports of active joints and of 'enthusiastic' responses during the progress of the trial, than his colleagues. It is tempting to consider that his manner was one which enabled the patient to express her own opinion without too much leading. In addition, it seems clear that the eliciting of large numbers of reports of toxicity and of active joints as well as of 'enthusiastic' reports in general during the progress of a trial tends to obscure rather than to illuminate the presence of genuine differences between drug effects.
Conclusion
In one obituary of Samuel Hyde (Brit. med. J. 1900) it was stated that he was an 'ardent believer in the means which he employed. He was an earnest advocate for balneary procedures and for climatic treatment in many chronic disorders and he prescribed them for his patients and recommended them in his writings with equal confidence'. He was evidently a master at producing the placebo response. I just wonder how he would have reacted to the views I have expressed to-day on the problems of clinical trials.
